A brain cancer drug beat its historical benchmark by nearly two and a half times, with a p-value most drugs never see, and the stock popped 19% before the open and closed down anyway on 20 times normal volume. A company that had been frozen out of trading for a missed filing came back to…
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Privacy Policy and Privacy Policy.